Physician profile
Budio J Thomas
NPI 1306948286
$9,611.15
in general payments reported to CMS, 2019-2025
25 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,903 · 2020: $1,005 · 2021: $1,028 · 2022: $734 · 2023: $1,548 · 2024: $1,287 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,940.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,862.61 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,473.34 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $1,185.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,064.41 | 2019-2025 | Ubrelvy, Vraylar |
| Abbott Laboratories | $546.96 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $541.94 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $537.13 | 2019-2022 | |
| Lilly USA, LLC | $469.45 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $450.15 | 2019-2023 | Austedo Xr |
| Pfizer INC. | $384.34 | 2019-2025 | |
| Mylan Specialty L.P. | $232.30 | 2019-2023 | Yupelri, Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.35 | 2019-2023 | Xifaxan, Trulance |
| Intuitive Surgical, INC. | $157.61 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.55 | 2022-2023 | Trintellix |
| Sumitomo Pharma America, INC. | $68.37 | 2024-2025 | Gemtesa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $65.50 | 2023 | Hetlioz |
| Glaxosmithkline, LLC. | $48.82 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $46.60 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $45.96 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $43.18 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $34.79 | 2023 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $30.54 | 2025 | Uptravi, Opsumit |
| Corcept Therapeutics | $29.14 | 2024 | Korlym |
| Esperion Therapeutics, INC. | $28.00 | 2024 | Nexletol |
| Echosens North America, INC. | $14.71 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Budio Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.